Skip to main content
DEINOVE logo

DEINOVE — Investor Relations & Filings

Ticker · ALDEI ISIN · FR0010879056 LEI · 969500BEJSRFER0F2K08 PA Professional, scientific and technical activities
Open in API
Filings indexed 300 across all filing types
Latest filing 2019-05-13 Environmental & Social …
Country FR France
Listing PA ALDEI

About DEINOVE

https://www.deinove.com

DEINOVE is a biotechnology company that discovers, develops, and produces high-value compounds derived from rare bacteria and microorganisms, often referred to as 'microbial dark matter'. Leveraging a proprietary technology platform, the company harnesses the metabolic potential of extremophilic bacteria, such as Deinococcus, to create innovative solutions. Its primary applications are focused on developing novel bio-based active ingredients, including carotenoids, for the cosmetics sector, and discovering new antibiotics to address the global challenge of antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Environmental & Social Information Classification · 1% confidence The document is a press release dated May 13, 2019, announcing scientific findings regarding a cosmetic ingredient (Phytoène) developed by DEINOVE and promoted by its partner Solvay at the NYSCC Suppliers' Day. It details the mechanism of action, scientific studies, commercial progress, and provides background information on DEINOVE and the ingredient. This type of announcement, focusing on scientific validation and commercial updates for a specific product/ingredient, is characteristic of an Investor Presentation (IP) or a general press release detailing business progress. Since it is a detailed announcement of scientific and commercial progress, rather than just a brief earnings highlight (ER) or a formal regulatory filing (RNS), 'Investor Presentation' (IP) is the most fitting category, as these often contain detailed strategic and scientific updates aimed at investors, even if formatted as a press release. It is not a formal financial report (10-K, IR) or a transcript (CT). Given the depth of scientific and commercial detail, IP is preferred over the general RNS.
2019-05-13 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated April 12, 2019, announcing that DEINOVE's Scientific Director will present progress on the DNV3837 antibiotic program at the 29th congress of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID). It details the scientific findings and the upcoming Phase II trial design. This is not a formal regulatory filing (like 10-K, IR, or ER), nor is it a general announcement of a report publication (RPA). It is an announcement detailing scientific/pipeline progress and participation in an industry event, which is best categorized as general Investor Information or a specific update related to R&D/pipeline progress. Given the options, it most closely resembles an Investor Presentation (IP) in content focus (pipeline update, data presentation), but since it is a press release *about* a presentation, and not the presentation itself, and it doesn't fit other specific categories like M&A (TAR) or Capital (CAP), the most appropriate general category for pipeline/scientific updates disseminated to investors, when the actual presentation document is not provided, is often the closest fit or the fallback. However, since it is a news announcement detailing scientific progress and upcoming trial plans, it functions as an update for investors. Since 'Investor Presentation' (IP) is defined as a detailed presentation, and this is a press release *about* a presentation, it is a borderline case. Given the focus on pipeline progress and clinical trial updates, it is a form of investor communication. If a specific 'Pipeline Update' category existed, it would fit there. Lacking that, and noting it is a formal announcement of scientific progress, it is closest to the spirit of an Investor Presentation (IP) or a general Regulatory Filing (RNS) if it were purely administrative. Since it contains substantial scientific and pipeline detail intended for investors, I will classify it as an Investor Presentation (IP) as it conveys the core information that would be in such a presentation, even if delivered via a press release format. If the document were shorter and just said 'We will present at ECCMID,' it would be RPA/RNS. Because it contains the substance of the update, IP is the best fit among the specific options.
2019-04-12 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated April 12, 2019, announcing that the Scientific Director of DEINOVE will present data on their DNV3837 program at the 29th annual congress of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID). This is an announcement about participation in a scientific conference, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an informational update directed towards investors and the public regarding scientific progress and presentation at an industry event. Since it is a general announcement that doesn't fit the specific categories like AGM-R, ER, IR, or CT, the most appropriate classification is the general Regulatory Filings category (RNS), as it serves as a broad communication of material, non-standardized information.
2019-04-12 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated April 9, 2019, announcing a new agreement between DEINOVE and the Institut Pasteur regarding the exploration of novel antibiotics using bacterial strains. It details a strategic partnership, mentions ongoing programs (AGIR), and includes quotes from executives. This type of announcement, focusing on a specific business development, partnership, or research milestone, is typically classified as a general regulatory announcement or press release that doesn't fit the strict definitions of 10-K, ER, or IR. Since it is a formal announcement of a strategic development and not a report itself, and it doesn't fit specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate classification is the general regulatory filing/announcement category, RNS, as it serves as a public disclosure of material information.
2019-04-09 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated April 9, 2019, announcing a strategic agreement between DEINOVE and the Institut Pasteur regarding the research of new antibiotics using bacterial strains. It details the collaboration, the AGIR program, and provides background information on both entities. This type of announcement, detailing a specific business development, partnership, or research milestone, is typically classified as a general regulatory announcement or press release that doesn't fit into the more specific financial reporting categories (like 10-K, ER, or IR). Since it is a formal announcement providing key operational news and is not a full report, a financial supplement, or a proxy statement, the most appropriate general category is Regulatory Filings (RNS), as it serves as a broad communication to the market.
2019-04-09 French
Inside Information / News release on accounts, results
Annual Report Classification · 1% confidence The document is a comprehensive report titled '2018 Annual Results' that includes detailed financial statements (Income Statement, Cash & Cash Equivalents), management's discussion of operational progress, and business outlook. It is not a short announcement or a certification letter, but rather the substantive financial report for the fiscal year 2018. Therefore, it is classified as an Annual Report (10-K). FY 2018
2019-03-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.